NWPHF 6.22 Newron Pharmaceuticals S.p.A.
| Range: | 5.22-12.0 | Vol Avg: | 755 | Last Div: | 0 | Changes: | 0.6 |
| Beta: | 0.64 | Cap: | 0.21B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Aug 30 2017 | Empoloyees: | 22 | ||
| CUSIP: | CIK: | ISIN: | Country: | IT | |||
| CEO: | Mr. Stefan Weber | Website: | https://www.newron.com | ||||
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow